Sino Biopharmaceutical Limited Press Release

Sino Biopharmaceutical (1177.HK) Announces 2024 Interim Results
Aug 14, 2024 00:30 JST

Sino Biopharmaceutical Limited (?Sino Biopharmaceutical? or the ?Company?, together with its subsidiaries, the ?Group?) (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited interim results for the six months ended 30 June 2024 (the ?Period?).
More info..

Sino Biopharm (1177.HK) Announces 2023 Annual Results
Mar 29, 2024 11:45 JST

Sino Biopharmaceutical Limited ("Sino Biopharm" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its audited financial results for the year ended 31 December 2023.
More info..

Sino Biopharmaceutical (1177.HK) Announces 2023 Interim Results
Aug 25, 2023 19:12 JST

Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited interim results for the six months ended 30 June 2023 (the "Period").
More info..

Sino Biopharm (1177.HK) Announces 2022 Annual Results
Mar 31, 2023 21:11 JST

Sino Biopharmaceutical (1177.HK) Announces 2022 lnterim Results, Revenue up by 5.9% to RMB15.19 billion
Aug 23, 2022 19:51 JST

Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited Interim results for the six months ended 30 June 2022 (the "Period").
More info..

Sino Biopharmaceutical Donates Cash and Supplies Valued at RMB10 Million to Support Henan for Flood Relief and Preventing Epidemic
Jul 22, 2021 19:26 JST

Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, has announced the donation of cash and supplies valued at RMB10 million to support Henan for flood relief and preventing epidemic.
More info..

Sino Biopharmaceutical 2021 First Quarterly Profit attributable to Owners of the Parent Soars 118.5% to RMB1.91 Billion
May 24, 2021 17:12 JST

Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited first quarterly results for the three months ended 31 March 2021.
More info..

Sino Biopharmaceutical 2020 Net Profit Grows to RMB2.77 Billion amid Adversity Mar 23, 2021 17:09 JST Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, has announced its audited annual results for the year ended 31 December 2020. More info..

Sino Biopharm Invests in Sinovac LS, A Leading COVID-19 Vaccine Company in China
Dec 07, 2020 08:55 JST

Sino Biopharmaceutical Limited ("Sino Biopharm" or the "Group"; HKEX: 1177) has announced the investment of US$515 million in Sinovac Life Sciences Co., Ltd. ("Sinovac LS", previously known as Sinovac Research and Development Co., Ltd.), which will be funded by internal resources of the Group and result in a 15.03% equity interest in Sinovac LS.
More info..

Sino Biopharmaceutical Announces 2020 Third Quarterly Results Nov 30, 2020 17:20 JST Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, More info..

Sino Biopharm Announces 2020 Interim Results
Aug 28, 2020 17:20 JST

Sino Biopharmaceutical Limited ("Sino Biopharm" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading, innovative research and development ("R&D") driven pharmaceutical conglomerate in the PRC, has announced its unaudited interim results for the six months ended 30 June 2020 (the "review period").
More info..

Sino Biopharmaceutical Announces 2020 First Quarterly Results
May 28, 2020 19:59 JST

Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading, innovative research and development ("R&D") driven pharmaceutical conglomerate in the PRC, has announced its unaudited first quarterly results for the three months ended 31 March 2020 ("the review period").
More info..

New Drug Application of Penpulimab Co-developed by Sino Biopharmaceutical and Akeso Accepted by the National Medical Products Administration
May 26, 2020 17:16 JST

Sino Biopharmaceutical Limited (HKEX: 1177), a leading, innovative research and development ("R&D") driven pharmaceutical conglomerate in the PRC, has announced that the new drug application of the anti PD-1 monoclonal antibody drug
More info..

Results from Clinical Trials of Penpulimab in Combination with Anlotinib for 1L HCC Co-developed by Sino Biopharmaceutical and Akeso Accepted for Presentation at ASCO Annual Meeting
May 19, 2020 17:50 JST

Sino Biopharmaceutical Limited (HKEX: 1177), a leading, innovative research and development ("R&D") driven pharmaceutical conglomerate in the PRC, has announced that the abstracts on phase II study on clinical efficacy and safety of Penpulimab
More info..

Sino Biopharm Announces 2019 Annual Results Mar 30, 2020 18:25 JST Sino Biopharmaceutical Limited ("Sino Biopharm" or the "Company", together with its subsidiaries, the "Group") (HKEX: 1177), a leading, innovative research and development driven pharmaceutical conglomerate in the PRC, has announced its financial results for the year ended 31 December 2019 ("the year"). More info..

Asia-Pacific has Record Year for Clinical Trials says Novotech CRO
Jan 21, 2020 10:40 JST

Novotech CRO the largest biotech CRO in the Asia-Pacific said the region has had a record year for number of studies, experienced world-class sites and investigators, and patient enrolment.
More info..

Sino Biopharmaceutical Announces 2019 Third Quarterly Results
Nov 26, 2019 19:50 JST

Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited third quarterly results for the nine months ended 30 September 2019 ("the review period").
More info..

Sino Biopharmaceutical Announces 2019 Interim Results
Aug 29, 2019 16:40 JST

Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, has announced today its unaudited interim results for the six months ended 30 June 2019 (the "review period").

More info..

Sino Biopharmaceutical Announces 2019 First Quarterly Results
May 22, 2019 10:40 JST

Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, has announced its unaudited first quarterly results for the three months ended 31 March 2019 ("the review period").

More info..

Sino Biopharmaceutical's 2018 Annual Results Reaches New Height
Apr 01, 2019 22:01 JST

Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Company", together with its subsidiaries, the "Group") (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, has announced its annual results for the year ended 31 December 2018.

More info..

Sino Biopharmaceutical Announces 2018 Third Quarterly Results Nov 26, 2018 09:34 JST Sino Biopharmaceutical Limited ("Sino Biopharmaceutical" or the "Group") (HKEX:1177), a leading and innovation-driven pharmaceutical conglomerate in the PRC, announced its unaudited third quarterly results for the nine months ended 30 September 2018 ("the review period"). More info..